397 related articles for article (PubMed ID: 18957672)
1. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
Sekeres MA; Schoonen WM; Kantarjian H; List A; Fryzek J; Paquette R; Maciejewski JP
J Natl Cancer Inst; 2008 Nov; 100(21):1542-51. PubMed ID: 18957672
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic growth factors in myelodysplastic syndromes.
Steensma DP
Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
[TBL] [Abstract][Full Text] [Related]
3. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa for anemia with myelodysplastic syndrome.
Seastone DJ; Gerds AT
Expert Rev Hematol; 2015 Apr; 8(2):139-46. PubMed ID: 25579702
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
8. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010.
Sekeres MA
J Natl Compr Canc Netw; 2011 Jan; 9(1):57-63. PubMed ID: 21233244
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
[TBL] [Abstract][Full Text] [Related]
11. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
13. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.
Duong VH; Baer MR; Hendrick F; Weiss SR; Sato M; Zeidan AM; Gore SD; Davidoff AJ
Leuk Res; 2015 Jun; 39(6):586-91. PubMed ID: 25869077
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
Santini V
Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
[TBL] [Abstract][Full Text] [Related]
15. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg PL; Cosler LE; Ferro SA; Lyman GH
J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
[TBL] [Abstract][Full Text] [Related]
16. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes.
Gotlib J; Lavori P; Quesada S; Stein RS; Shahnia S; Greenberg PL
Am J Hematol; 2009 Jan; 84(1):15-20. PubMed ID: 19006226
[TBL] [Abstract][Full Text] [Related]
17. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome.
Hofmann WK; Koeffler HP
Annu Rev Med; 2005; 56():1-16. PubMed ID: 15660498
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
